Poland· PL-100442278
Entyvio
A vedolizumab product containing vedolizumabum, registered in Poland by Takeda Pharma A/S. The same ATC class is registered in 12 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Vedolizumab is registered in 12 of 19 countries.
Countries holding a registration under ATC L04AG05 (vedolizumab), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 8 of them publish a price we can compare per daily dose
Vedolizumab · ATC L04AG05
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of vedolizumab costs, country by country.
Normalised to the WHO defined daily dose (5.4 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Vedolizumab · price per daily dose (5.4 mg)
USD · FX 28 Sept 2026
- CH Switzerland$36.68
The record
At a glance
URPL (Poland)- Active substance
- Vedolizumabum
- Manufacturer
- Takeda Pharma A/S
- Country
- Poland (PL)
- ATC code
- L04AG05
- ATC class
- Vedolizumab
- Defined daily dose
- 5.4 mg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 2
- gtin07038319122857
- gtin07038319122864
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
60 interactions on record for vedolizumab.
Graded by severity as the source publishes them — 27 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Vedolizumab · interactions on record
60 records
- 27 severe
- 26 moderate
- 7 minor
Most severe, free to view
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Vedolizumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaENTYVIOTakeda Pharma A/S, Vallensbaek Strand
- SwedenEntyvio 108 mg Injektionsvätska, lösning i förfylld injektionspennaTakeda Pharma A/S
- SpainENTYVIO 108 MG SOLUCION INYECTABLE EN JERINGA PRECARGADATakeda Pharma A/S
- BelgiumEntyvio 108 mgTakeda Pharma
- IcelandEntyvioTakeda Pharma A/S
- IrelandEntyvio 108 mg solution for injection in pre-filled penTakeda Pharma A/S
- NorwayEntyvioTakeda Pharma A/S (1)
- FinlandEntyvioTakeda Pharma A/S
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Entyvio
- Liechtenstein · Entyvio
- Norway · Entyvio
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/752a8564-4565-45a1-8e82-8f297aded710 GET /v1/drugs/752a8564-4565-45a1-8e82-8f297aded710?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do wstrzykiwań",
"source": "urpl",
"strength": "108 mg",
"packaging": "Rpz ¦ EU/1/14/923/002 ¦ 138038\n1 amp.-strzyk. 0,68 ml\nRpz ¦ EU/1/14/923/005 ¦ 138039\n1 wstrzykiwacz 0,68 ml\n07038319122857 ¦ Rpz ¦ EU/1/14/923/006 ¦ 138040\n2 wstrzykiwacze 0,68 ml\n07038319122864 ¦ Rpz ¦ EU/1/14/923/003 ¦ 138041\n2 amp.-strzyk. 0,68 ml\nRpz ¦ EU/1/14/923/004 ¦ 138042\n6 amp.-strzyk. 0,68 ml\nRpz ¦ EU/1/14/923/007 ¦ 138043\n6 wstrzykiwaczy 0,68 ml",
"substance": "Vedolizumabum 108 mg",
"common_name": "Vedolizumabum",
"pl_product_id": "100442278",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about vedolizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.